I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ARVO 2023

-
Coming soon
12:45 PM
Duration 15mins La Nouvelle AB
Durable vision gains and greater fluid control with extended faricimab▼ dosing versus aflibercept in patients with diabetic macular edema
Lim J, Chen SJ, Steinle N, Jaffe G, Gerendas B, Abreu F, Camino A, Gibson K, Jain N, Shildkrot E, Souverain A, Tang Y, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:00 PM
Duration 15mins La Nouvelle AB
Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With Diabetic Macular Edema
Goldberg R, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, Wang T, Haskova Z, Shildkrot E, Amador M, Mar F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:15 PM
Duration 15mins La Nouvelle AB
Faster time to retinal fluid control with faricimab▼ in patients with DME in the phase 3 YOSEMITE/RHINE trials
Pollreisz A, Camino A, Gibson K, Mar F, Shildkrot E, Tang Y, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:00 AM
Duration 15mins La Nouvelle AB
Port Delivery System With Ranibizumab in the Treatment of Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pavilion Trial
Emanuelli A, Holekamp N, Latkany P, Brittain C, Quezada-Ruiz C, Howard D, Santhanakrishnan A, Wetzel-Smith M, Malhotra V, Pieramici D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:30 PM
Duration 15mins La Nouvelle AB
Visual function loss in geographic atrophy: learnings from lampalizumab trial data
Steffen V, Anegondi N, Ferrara D, Chakravarthy U

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:45 AM
Duration 15mins La Nouvelle AB
Individualized faricimab▼ dosing up to every 16 weeks maintains robust anatomic and vision outcomes through 2 years in nAMD
Chaudhary V, Kotecha A, Willis J, Souverain A, Shildkrot E, Swaminathan B, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:30 AM
Duration 15mins La Nouvelle AB
A novel intravitreal anti-IL-6 monoclonal antibody for UME: preliminary results from the phase 1 DOVETAIL study
Sharma S, Suhler E, Lin P, Pauly-Evers M, Willen D, Peck R, Storti F, Rauhut S, Gott T, Passemard B, Macgregor L, Haskova Z, Silverman D, Fauser S, Mesquida M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar